Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- The FDA has issued a Complete Response Letter (CRL) to Ardelyx Inc's (NASDAQ:ARDX) marketing application seeking approval for tenapanor to control serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
- While the FDA agrees that "the submitted data provide substantial evidence that tenapanor is effective in reducing serum phosphorus in CKD patients on dialysis," they characterize the magnitude of the treatment effect as "small and of unclear clinical significance."
- Additionally, FDA asked Ardelyx to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect.
- There were no safety, clinical pharmacology/biopharmaceutics, CMC, or non-clinical issues identified in the CRL.
- At the end of the second quarter ended June 30, 2021, Ardelyx had $171.8 million in cash and cash equivalents.
- Price Action: ARDX shares are trading 15.8% higher at $1.98 during the market session on the last check Friday.
- Related content: Benzinga's Full FDA Calendar.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!